# Alchemab Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alchemab-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.alchemab.com
- Total disclosed funding: $121M
- Investors on record: 9

## About

Alchemab Therapeutics Ltd, based in the UK, is a biopharmaceutical company focused on developing innovative antibody therapeutics aimed at addressing complex and hard-to-manage diseases.Founded in 2019 in London, UK, Alchemab Therapeutics specializes in the development of antibody therapeutics. The company has engaged in five funding deals, with its most recent round being a Grant of GBP 1.7 million led by the UK Technology Strategy Board on December 16, 2022. The total amount raised by the company is GBP 40.0 million. The CEO is Young Kwon, and the founder is Rachael Bashford-Rogers.Alchemab Therapeutics specializes in the development of next-generation antibody therapeutics aimed at treating hard-to-manage diseases. The company's focus lies in leveraging the immune system's adaptive immunity to create therapeutics based on antibodies found in resilient individuals, such as long-term cancer survivors. This innovative approach employs advanced scientific methodologies and deep learning techniques to identify and develop these therapeutic antibodies, targeting markets primarily in North America and Europe.Alchemab Therapeutics generates revenue through strategic partnerships and licensing agreements with major pharmaceutical companies. These transactions typically involve the licensing of proprietary antibody therapeutics, allowing partners to incorporate these innovations into their own development pipelines, supported by collaborations that involve milestone payments and royalties based on product performance in the market.In December 2022, Alchemab Therapeutics secured GBP 1.7 million in funding to support its initiatives in triaging a panel of antibodies for first-in-human studies. The company is focused on expanding its product offerings and is actively designing new therapeutics aimed at addressing diseases that lack effective treatments. The strategic funding will enable Alchemab to advance its research and commercialization efforts, targeting further expansion in both North American and European markets by upcoming release dates.

## Funding rounds

- Round, Oct 16, 2026, $33M — British Business Bank
- Series A, Jul 3, 2025, $33M — Lilly Ventures, SV Health Investors, DCVC, Lightstone Ventures, RA Capital Management, Ono Venture Investment
- Series A, Apr 15, 2021, $55M — SV Health Investors, DCVC, Lightstone Ventures, RA Capital Management, DHVC, Dementia Discovery Fund
- Seed, Dec 1, 2019 — DCVC
- Seed, Jun 1, 2019 — SV Health Investors

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed, Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- DHVC (https://capitalatlas.ai/funds/dhvc) — Series A
- Dementia Discovery Fund — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Ono Venture Investment (https://capitalatlas.ai/funds/ono-venture-investment) — Series A
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank)